Burning Rock Biotech Limited services

Burning Rock proprietary database intelligent screening system screens reports, and regularly identifies patients with rare or specific genetic variants;

Burning Rock offers integrated companion diagnostic development services for biopharma partners to streamline the co-development and commercialization of targeted drugs and respective CDx （including registration testing, clinical evaluation and finally obtain registration certificates. Our US-based lab and R&D team provide additional services to promote drug and CDx co-development worldwide.

Burning Rock utilizes our own proprietary large-scale genomic dataset based on personalized analyses of Chinese cancer patients*, ntegrates the experience from multi-dimensional clinical/scientific research and published data, to provide a one-stop cancer genomic data solution for biopharma partners, aiming to speed up precision drug development and reduce the risks. Burning Rock provides effective biomarker clinical trial strategies for biopharma partners, including indication selection, patient screening and stratification, drug efficacy/mechanism exploration and recommendation of clinical study sites.

Burning Rock offers integrated central lab services for biopharma partners, from multimodal sample testing to data analysis, meeting drug developing requirement, with four industry-leading qualifications (CLIA, CAP, NCCL, and NMPA) and full spectra of diagnostic products. So far, we have provided central lab services with >50 clinical research studies for >30 pharmaceutical companies, covering clinical study sites globally.